Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A cerebral amyloid angiopathy characterized by ataxia, intention tremor, psychosis and dementia that has material basis in an autosomal dominant mutation of ITM2B on chromosome 13q14.2.
Features include: Psychosis, Hearing loss (hearing impairment), Cerebral amyloid angiopathy, and Progressive loss of mental abilities (dementia) and 5 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Psychosis, Cerebral amyloid angiopathy, Progressive loss of mental abilities (dementia) |
ITM2B encodes integral membrane protein 2B (266 aa). Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Highest expression in Ovary (241.1 TPM) and Whole Blood (208.7 TPM).
ADan amyloidosis is associated with mutations in the ITM2B gene on chromosome 13.
ITM2B is classified as a druggable target (Druggable Genome category) with score 0.0.
Genetic testing for ITM2B is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ADan amyloidosis has been reported in the published literature.
No clinical trials have been registered for ADan amyloidosis.
5 publications have been identified in PubMed for ADan amyloidosis. Research spans Basic Science / Preclinical (80%) and Diagnostic / Biomarker (20%).
Zhang Z (2026). [PMID: 41386615](https://pubmed.ncbi.nlm.nih.gov/41386615/). *Int J Biol Macromol*. [Basic Science / Preclinical]
Jury-Garfe N (2025). [PMID: 40346706](https://pubmed.ncbi.nlm.nih.gov/40346706/). *Alzheimers Dement*. [Basic Science / Preclinical]
Choudhury A (2025). [PMID: 41354963](https://pubmed.ncbi.nlm.nih.gov/41354963/). *J Neuroinflammation*. [Basic Science / Preclinical]
Martín M (2025). [PMID: 40314981](https://pubmed.ncbi.nlm.nih.gov/40314981/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Wojtas AM (2024). [PMID: 38713744](https://pubmed.ncbi.nlm.nih.gov/38713744/). *Alzheimers Dement*. [Diagnostic / Biomarker]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 1:59 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ADan amyloidosis
Ears
1 |
Hearing loss (hearing impairment) |
Eyes | 1 | Posterior polar cataract |
AI-curated news mentioning ADan amyloidosis
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.